These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 19150343)

  • 1. Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: advances and open questions.
    Bock KW; Köhle C
    Biochem Pharmacol; 2009 May; 77(9):1458-65. PubMed ID: 19150343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of UDP glucuronosyltransferase membrane association and residency in the endoplasmic reticulum.
    Meech R; Mackenzie PI
    Arch Biochem Biophys; 1998 Aug; 356(1):77-85. PubMed ID: 9681994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.
    Miners JO; Knights KM; Houston JB; Mackenzie PI
    Biochem Pharmacol; 2006 May; 71(11):1531-9. PubMed ID: 16455060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic properties of UDP-glucuronosyltransferase(S) in different membranes of rat liver cells.
    Antoine B; Magdalou J; Siest G
    Xenobiotica; 1984 Jul; 14(7):575-9. PubMed ID: 6438924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
    Miners JO; Mackenzie PI; Knights KM
    Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A functional role for histidyl residues of the UDP-glucuronic acid carrier in rat liver endoplasmic reticulum membranes.
    Battaglia E; Radominska-Pandya A
    Biochemistry; 1998 Jan; 37(1):258-63. PubMed ID: 9425046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.
    Williams JA; Hyland R; Jones BC; Smith DA; Hurst S; Goosen TC; Peterkin V; Koup JR; Ball SE
    Drug Metab Dispos; 2004 Nov; 32(11):1201-8. PubMed ID: 15304429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification.
    Iyanagi T
    Int Rev Cytol; 2007; 260():35-112. PubMed ID: 17482904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttranscriptional regulation of uridine diphosphate glucuronosyltransferases.
    Riches Z; Collier AC
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):949-65. PubMed ID: 25797307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of UDP-glucuronosyltransferases in membranes.
    Radominska-Pandya A; Ouzzine M; Fournel-Gigleux S; Magdalou J
    Methods Enzymol; 2005; 400():116-47. PubMed ID: 16399347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators.
    Knights KM; Miners JO
    Drug Metab Rev; 2010 Feb; 42(1):63-73. PubMed ID: 19780654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UDP-glucuronosyltransferases and clinical drug-drug interactions.
    Kiang TK; Ensom MH; Chang TK
    Pharmacol Ther; 2005 Apr; 106(1):97-132. PubMed ID: 15781124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucuronate, the precursor of vitamin C, is directly formed from UDP-glucuronate in liver.
    Linster CL; Van Schaftingen E
    FEBS J; 2006 Apr; 273(7):1516-27. PubMed ID: 16689937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.
    Kaivosaari S; Finel M; Koskinen M
    Xenobiotica; 2011 Aug; 41(8):652-69. PubMed ID: 21434773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent data on the metabolism of drugs by UDP-glucuronosyltransferases and sulfotransferases (author's transl)].
    Batt AM; Magdalou J; Martin N; Lepage C; Kiffel L; Siest G
    Ann Biol Clin (Paris); 1980; 38(1):35-47. PubMed ID: 6769373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro glucuronidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases.
    Tong Z; Li H; Goljer I; McConnell O; Chandrasekaran A
    Drug Metab Dispos; 2007 Dec; 35(12):2203-10. PubMed ID: 17875670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of xenobiotic glucuronidating enzymes in drug resistance of tumour tissues and cells.
    Burchell B; Baird S; Coughtrie MW
    Princess Takamatsu Symp; 1990; 21():263-75. PubMed ID: 1966888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
    Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
    Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights.
    Tripathi SP; Bhadauriya A; Patil A; Sangamwar AT
    Drug Metab Rev; 2013 May; 45(2):231-52. PubMed ID: 23461702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins.
    Green MD; Tephly TR
    Drug Metab Dispos; 1998 Sep; 26(9):860-7. PubMed ID: 9733664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.